A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist
Open Access
Abstract
A single-protein or -peptide vaccine is not sufficient to arouse immune responses in cancer therapy. A whole-tumor-cell vaccine with complete cancer cell antigens and all conformations elicits robust immune responses and is a promising method for the treatment of advanced malignant tumors. In this study, we used 5-azacitidine to stimulate B16-F10 melanoma cells to express toll-like receptor (TLR) 3 on the cell surface and then chemically linked SZU-106, a small-molecule TLR7 agonist, to the cell surface with a pegylated linker to produce a novel whole-tumor-cell vaccine, abbreviated as Aza-BFcell-106. The vaccine stimulated mouse splenic lymphocytes and bone marrow-derived dendritic cells to secrete cytokines, promoted the maturation of dendritic cells and enhanced the capability of dendritic cells to present antigens. In a mouse model of melanoma, the vaccine effectively inhibited tumor growth, decreased tumor volume and prolonged survival. Further combination of the vaccine with a chemokine inhibitor, reparixin, significantly increased the infiltration of CD4+ and CD8+ T cells into the tumor environment, while the antitumor effect was significantly enhanced. The whole-tumor-cell vaccine Aza-BFcell-106 induced immune-activating responses in both in vitro and in vivo experiments, indicating that this vaccine has great potential to treat advanced malignant tumors.Keywords
Funding Information
- National Natural Science Foundation of China (81773939, JCYJ20210324094005015, JCYJ 20170818141120342, 2018A0303130262)
- Science and Technology Foundation of Shenzhen City (81773939, JCYJ20210324094005015, JCYJ 20170818141120342, 2018A0303130262)
- the Natural Science Foundation of Guangdong provincial (81773939, JCYJ20210324094005015, JCYJ 20170818141120342, 2018A0303130262)
This publication has 28 references indexed in Scilit:
- Unraveling the molecular pathways of DNA-methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumorsOncoImmunology, 2015
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCell, 2015
- Hyaluronan Binding Identifies a Functionally Distinct Alveolar Macrophage–like Population in Bone Marrow–Derived Dendritic Cell CulturesThe Journal of Immunology, 2015
- Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphomaJournal of Hematology & Oncology, 2015
- Overview of the cancer vaccine fieldHuman Vaccines & Immunotherapeutics, 2012
- Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell VaccinesInternational Reviews of Immunology, 2011
- Whole tumor antigen vaccinesSeminars in Immunology, 2010
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccinesCancer Immunology, Immunotherapy, 2008
- Overview of Tumor Cell–Based VaccinesInternational Reviews of Immunology, 2006
- Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).Proceedings of the National Academy of Sciences, 1995